Skip to main content

Table 1 Baseline clinical characteristics by different outcomes and treatment groups

From: On-treatment mortality predictors in chronic hepatitis B patients experiencing severe acute exacerbation: a prospective observational study

  All Survival Mortality p Telbivudine Entecavir p
Patient no 21 17 4   9 12  
Age 48 (28–71) 49 (28–71) 36.5 (29–51) 0.226 48 (29–65) 47 (28–71) 0.859
Gender     1.000    1.000
  Male 18 14 4 8 10
  Female 3 3 0 1 2
LdT/ETV 9/12 7/10 2/2 1.000
Mortality 2 2 1.000
HBeAg+ 9 7 2 1.000 3 6 0.660
Cirrhosis 3 2 1 0.489 1 2 1.000
Ascites 3 1 2 0.080 1 2 1.000
Encephalopathy 1 1 0 0.190 1 0 0.429
FU (M) 19.4 (0.8–28.2) 25.0 (4.0–28.2) 1.45 (0.8–2.5) 0.002 5.1 (1.9–28.2) 24.7 (0.8–27.7) 0.722
Albumin 3.49 (2.5–4.9) 3.6 (2.5–4.9) 2.95 (2.5–3.3) 0.020 3.6 (2.9–4.2) 3.4 (2.5–4.9) 0.477
ALT 1270 (146–2480) 1270 (211–2480) 1197 (146–2247) 0.929 1523 (211–2480) 870 (146–2247) 0.177
Bilirubin T 9.2 (2.1–33.1) 7.7 (2.1–16.8) 20.6 (11.9–33.1) 0.007 8.6 (2.1–20.4) 10.25 (2.2–33.1) 0.356
Creatinine 0.68 (0.39–1.46) 0.71 (0.47–1.34) 0.48 (0.39–1.46) 0.165 0.71 (0.47–1.05) 0.63 (0.39–1.46) 0.972
eGFR        
  MDRD 116 (53–254) 116 (53–183) 194.5 (54–254) 0.106 116 (73–201) 127 (53–254) 0.831
  CKD-EPI 111.1 (52.9–156.7) 110.1 (52.9–131.1) 138.2 (59.8–156.7) 0.152 112 (77.8–148) 110.6 (52.9–156.7) 0.722
Platelet (103) 148 (44–253) 148 (62–253) 121.5 (44–174) 0.244 174 (44–251) 121.5 (62–253) 0.188
INR 1.6 (1.3–3.5) 1.5 (1.3–2.3) 3.3 (2.6–3.5) 0.002 1.5 (1.3–3.1) 1.6 (1.4–3.5) 0.773
AFP 65.7 (4.1–650.7) 49.4 (4.1–477.2) 109.5 (27.9–650.7) 0.325 27.9 (4.2–238.3) 162.1 (4.1–650.7) 0.088
HBV DNA (log10 cps/ml) 8.04 (4.3–9.68) 8.16 (5.22–9.68) 5.06 (4.30–8.20) 0.031 8.04 (4.97–9.47) 8.04 (4.30–9.68) 0.886
MELD score 20 (13–37) 19 (13–28) 31.5 (26–37) 0.003 19 (14–31) 20 (13–37) 0.412
  1. Data shown as median (range); eGFR estimated glomerular filtration rate, MDRD modification of diet in renal disease (mL/min/1.73m2), CKD-EPI Chronic Kidney Disease Epidemiology Collaboration (mL/min/1.73m2), INR international normalized ratio, AFP alpha-fetoprotein, MELD model for end-stage liver disease.